Join
Live feed
·
PRReleasevia Quantisnow
NexImmune Inc. logo

NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers

ByQuantisnow·Wall Street's wire, on your screen.
NEXI· NexImmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NEXI (NexImmune Inc.) and more on Quantisnow.